General
Preferred name
INDINAVIR
Synonyms
L735524 sulfate ()
MK-639 sulfate ()
INDINAVIR SULFATE ()
Indinavir (sulfate) ()
MK-639 (free base) ()
L-735524 (free base) ()
MK-639 ()
L735524 ()
Crixivan, L-735524, MK-639 ()
INDINAVIR ANHYDROUS ()
Crixivan ()
Indinavir sulfate ethanolate ()
Indinaviri sulfas ()
NSC-697197 ()
L-735,524 ()
L-735524 ()
Indinavir sulphate ()
Indinavir-d6 ()
Indinavir system suitability ()
Indinavir monohydrate ()
P&D ID
PD010161
CAS
157810-81-6
150378-17-9
185897-02-3
180683-37-8
Tags
available
drug
drug candidate
Approved by
FDA
First approval
1996
Drug indication
Kaposi's sarcoma
Human immunodeficiency virus infection
Ewing sarcoma
Drug Status
approved
withdrawn
investigational
Max Phase
3.0
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Indinavir sulfate (MK-639) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir sulfate is also a SARS-CoV 3CLpro inhibitor[1][2][3][4].
PRICE 29
DESCRIPTION Indinavir is an anti-HIV-1 agent. It inhibits the viral protease. (GtoPdb)
DESCRIPTION Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CLpro inhibitor[1][2][3][4].
DESCRIPTION Indinavir is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV infection and AIDS. It inhibits the HIV-1 protease with an IC50 value of 0.41 nM and Ki value of 0.24 nM. However, indinavir demonstrates up to a 50-fold loss in potency against the HIV-1 protease drug-resistant mutations PRL24I, PRI50V, and PRG73S (Kis = 1.4, 27, and 0.55 nM). (BOC Sciences Bioactive Compounds)
DESCRIPTION Indinavir is an HIV-1 protease inhibitor. It is used in combination with antiretroviral agents in the treatment of HIV infection. (Enamine Bioactive Compounds)
DESCRIPTION Indinavir sulfate (L735524 sulfate) is a HIV protease inhibitor.It inhibits the HIV-1 protease with an IC50 value of 0.41 nM and Ki value of 0.24 nM. (TargetMol Bioactive Compound Library)
DESCRIPTION Indinavir is a member of the novel hydroxyaminopentane amide class of HIV-1 protease inhibitors. Indinavir is used as an antiviral. (BOC Sciences Bioactive Compounds)
Cell lines
2
Organisms
9
Compound Sets
22
BOC Sciences Bioactive Compounds
indinavir-sulfate-cas-157810-81-6-340297
indinavir-cas-150378-17-9-item-84-59389
Cayman Chemical Bioactives
15150
29585
ChEMBL Approved Drugs
CHEMBL1735
CHEMBL115
ChEMBL Drugs
CHEMBL1735
CHEMBL115
CHEMBL5483011
Drug Repurposing Hub
DrugBank
DB00224
DrugBank Approved Drugs
DB00224
DrugCentral
1437
DrugCentral Approved Drugs
1437
DrugMAP
DM0T3YH
DrugMAP Approved Drugs
DM0T3YH
Enamine Bioactive Compounds
EBC-08495
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100846
Guide to Pharmacology
12684
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL115
MedChem Express Bioactive Compound Library
HY-B0689A
HY-B0689
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
Selleckchem Bioactive Compound Library
indinavir-sulfate
TargetMol Bioactive Compound Library
T5863
External IDs
88
Properties
(calculated by RDKit )
Molecular Weight
613.36
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
4
Rotatable Bonds
11
Ring Count
5
Aromatic Ring Count
3
cLogP
2.87
TPSA
118.03
Fraction CSP3
0.47
Chiral centers
5.0
Largest ring
6.0
QED
0.26
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
HIV Protease
SARS-CoV
CYP3A4, CYP3A5, CYP3A7
Apoptosis
MMP
COVID-19,HIV Protease
Indication
human immunodeficiency virus (HIV-1)
MOA
HIV Protease inhibitor
Therapeutic Class
Anti-HIV Agents
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Metabolic Enzyme/Protease
Solubility
In vitro:<br/>10 mM in DMSO
In Vitro:<br/>DMSO : ≥ 100 mg/mL (140.48 mM)<br/>H2O : 50 mg/mL (70.24 mM
Need ultrasonic)
Source data